Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
Juan R. Luciano, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 19.826 shares (reported with a price of $748.19 per share) and indicates 16,455.857 shares beneficially owned following the transaction in a direct ownership form. The filing explains these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person’s separation from service. The Form 4 was signed on behalf of Mr. Luciano on 09/17/2025 by an authorized filer.
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported an internal acquisition of common stock on 09/15/2025. The filing shows 2,003.492 shares were acquired and recorded as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares following the reporting person's separation from service. The report lists a per-share amount of $748.19 associated with the transaction. The reporting person disclaims beneficial ownership except to the extent of a pecuniary interest, noting the shares are held by a trust. The Form 4 was signed on behalf of Hedley by Jonathan Groff on 09/17/2025.
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported an acquisition on 09/15/2025 of 74,751.392 shares of common stock. The Form 4 lists a per-share price of $748.19. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service. The report is signed on behalf of Fyrwald on 09/17/2025.
Ralph Alvarez, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 15.705 common stock units at a reported price of $748.19, and after the transaction the reporting person is shown as beneficially owning 55,137.85 shares (direct) and 758 shares indirectly through a trust. The filing discloses these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock following the reporting person’s separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
Edgardo Hernandez, EVP & President, Manufacturing Operations at Eli Lilly & Co. (LLY), reported changes in ownership on a Form 4. On 09/05/2025 he disposed of 17 shares of Eli Lilly common stock in a transaction coded G at a price of $0. After the reported disposition he directly beneficially owned 39,731.435 shares and indirectly held 872.3 shares through a 401(k). No derivative securities were reported. The form was signed on behalf of Mr. Hernandez on 09/08/2025.
Form 144 notice for Eli Lilly & Co. (LLY) reports a proposed sale of 2,000 common shares through Morgan Stanley Smith Barney LLC on 08/28/2025 on the NYSE with an aggregate market value of $1,468,340.00. The shares were acquired as Restricted Stock Units on 02/09/2022 from the issuer and payment information is listed as N/A.
The filer reports no securities sold during the past three months. The form includes the standard representation that the selling person is not aware of undisclosed material adverse information and provides space for signature and plan-adoption dates, but those fields are not populated in the supplied content.
Kenneth L. Custer, EVP & President, Card Met Hlth at Eli Lilly & Co (LLY), reported insider transactions dated 08/27/2025 and filed 08/28/2025. The filing shows a disposition of 9,346.902 shares of Eli Lilly common stock. It also reports a reallocation within the reporting person's deferred compensation account resulting in 612.937 shares of phantom stock (payable in cash after employment termination). After the reported transactions, the filing states the reporting person beneficially owns 2,173.461 shares of common stock. The form is signed on behalf of Mr. Custer by an authorized representative.
Donald A. Zakrowski, Senior Vice President, Finance & Chief Accounting Officer at Eli Lilly & Co. (LLY), reported a sale of 1,000 shares of Eli Lilly common stock on 08/28/2025 at a price of $734.93 per share. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on November 20, 2024. After the transaction, the reporting person beneficially owned 3,839.659 shares directly and 1,725.72 shares indirectly (401(k)). The Form 4 was signed by an authorized representative on behalf of Mr. Zakrowski.
Eli Lilly & Company filed an 8-K disclosing documentation related to a debt offering. The filing includes an Underwriting Agreement dated August 18, 2025, an Indenture (originally dated February 1, 1991) and a Tripartite Agreement appointing Deutsche Bank Trust Company Americas as successor trustee. The exhibits provide forms of Fixed Rate and Floating Rate Notes, including a Floating Rate Note due 2028 and fixed-rate notes with stated coupons of 4.000% (2028), 4.250% (2031), 4.550% (2032), 4.900% (2035), 5.550% (2055) and 5.650% (2065). Legal opinions by Kirkland & Ellis LLP and Jamie Burnett, Esq., and their consents are included, as well as a Cover Page Interactive Data File. The filing is signed by Jon Haug, Senior Vice President, Treasurer and Corporate Finance and Investment Banking, dated August 20, 2025.
Gabrielle Sulzberger, a director of Eli Lilly & Co. (LLY), reported an acquisition of 2,710.158 shares of common stock on 08/18/2025. The filing shows the shares were acquired at a price of $698.05 and, at the reporting person’s election, have been deferred as stock units under the Lilly Directors' Deferral Plan. Those units will be settled in shares of common stock following the reporting person’s separation from service. The Form 4 was signed and submitted on 08/19/2025.